Across the recent three months, 8 analysts have shared their insights on Globus Medical (NYSE:GMED), expressing a variety of opinions spanning from bullish to bearish.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

In the assessment of 12-month price targets, analysts unveil insights for Globus Medical, presenting an average target of $72.0, a high estimate of $85.00, and a low estimate of $60.00. Marking an increase of 9.92%, the current average surpasses the previous average price target of $65.50.

Exploring Analyst Ratings: An In-Depth Overview

In examining recent analyst actions, we gain insights into how financial experts perceive Globus Medical. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Globus Medical's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.

Stay up to date on Globus Medical analyst ratings.

About Globus Medical

Globus Medical's Economic Impact: An Analysis

Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.

Revenue Growth: Globus Medical displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 119.26%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: Globus Medical's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -1.17%, the company may face hurdles in effective cost management.

Return on Equity (ROE): Globus Medical's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -0.18%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): Globus Medical's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.14%, the company may face hurdles in generating optimal returns from its assets.

Debt Management: Globus Medical's debt-to-equity ratio is below the industry average at 0.13, reflecting a lower dependency on debt financing and a more conservative financial approach.

The Significance of Analyst Ratings Explained

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga's automated content engine and reviewed by an editor.